Cannabis Users With Schizophrenia Had Lower Rates of Metabolic Syndrome

In 988 CATIE study participants with schizophrenia, THC-positive individuals (14.8%) had significantly lower metabolic syndrome prevalence (42.5% vs 60.5%, p < 0.001). After adjusting for confounders, cannabis use remained associated with reduced MetS odds (adjusted OR 0.64, 95% CI: 0.44-0.93, p = 0.02) and lower waist circumference (adjusted OR 0.61, 95% CI: 0.41-0.91).

Cross-sectional analysis of 988 participants with DSM-IV schizophrenia from the CATIE study. Cannabis use was objectively measured via hair testing for THC. Metabolic syndrome was defined by International Diabetes Federation criteria. Multivariable logistic regression adjusted for demographics, smoking, and other substance use.

Metabolic syndrome is extremely common in schizophrenia (often exceeding 50%) and drives cardiovascular mortality. Understanding why cannabis users have lower rates could reveal metabolic pathways worth targeting, though the cross-sectional design limits causal interpretation.

This finding is consistent with broader population studies showing lower obesity rates among cannabis users. In schizophrenia, where antipsychotic medications frequently cause metabolic side effects, understanding this association could be particularly valuable.

Cross-sectional design cannot determine causation. Cannabis users may differ from non-users in ways not fully captured by covariates (diet, activity levels, illness severity). Hair testing captures recent use but not lifetime exposure patterns.